{
    "rcn": "209455",
    "acronym": "ADAPT-SMART",
    "topics": "IMI2-2015-04-01",
    "title": "Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes",
    "startDate": "01/07/2015",
    "endDate": "31/12/2017",
    "objective": "Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major adaptations to current paradigms of bringing medicines to patients are required in order to realize that potential and to address important challenges in the healthcare ecosystem.\nAgainst this background, several initiatives are exploring new pathways to market, collectively referred to as Medicines Adaptive Pathways to Patients (MAPPs).\nThe ADAPT-SMART consortium is aligning a limited number of major stakeholders eager to progress towards MAPPs implementation. It will act as a neutral collaborative platform that will engage industry, SMEs, regulators, Health Technology Assessment bodies (HTAs), payers, governments, clinicians and patients. \nThe ADAPT-SMART consortium will contribute to align understanding of the impact of MAPPs, to share learnings between all stakeholders, and to allow the field to actively work towards MAPPs implementation.\nThe impact of the ADAPT-SMART CSA will be a result of the delivery of:\nï\tActionable advice/recommendations to IMI on how to best leverage results from past/current projects;\nï\tConcrete proposals for future (IMI) projects;\nï\tActionable advice/recommendations and information to other actors in the healthcare environment;\nï\tAynthesis of learnings from pilot projects and case studies with relevance to MAPPs;\nï\tCommunication of CSA outcomes by way of publications and conference presentations.\nThis CSA will increase the probability of successful implementation of MAPPs and accelerate access to crucial therapies, thus improving the position of both the patients in need of novel treatments and the research-based pharmaceutical industry.",
    "totalCost": "4039646",
    "ecMaxContribution": "1130000",
    "coordinator": "STICHTING LYGATURE",
    "coordinatorCountry": "NL",
    "participants": "PFIZER LIMITED;AbbVie Ltd;GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.;UCB BIOPHARMA SPRL;EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION;NOVARTIS PHARMA AG;FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES;IPSEN INNOVATION S.A.S.;MERCK SHARP & DOHME CORP;ASTRAZENECA AB;Amgen NV;F. HOFFMANN-LA ROCHE AG;MASSACHUSSETTS INSTITUTE OF TECHNOLOGY MIT CORPORATION;NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE;FORUM EUROPEEN DES PATIENTS (FPE);Bayer Pharma AG;H. LUNDBECK AS;Boehriger Ingelheim International GmbH;Danish Health and Medicines Authority;Haute AutoritÈ de SantÈ;Lysogene;AGENZIA ITALIANA DEL FARMACO;ASTELLAS PHARMA EUROPE LTD;THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD;Shire International GmbH;SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT;NOVO NORDISK A/S;INSTITUT DE RECHERCHES INTERNATIONALES SERVIER;Eli Lilly and Company Limited;European Medicines Agency;BRISTOL-MYERS SQUIBB COMPANY CORP;JANSSEN PHARMACEUTICA NV;Zorginstituut Nederland;Merck KGaA",
    "participantCountries": "UK;BE;FR;CH;US;SE;LU;DE;DK;IT;NL",
    "projectParticipants": {
        "999913249": {
            "orgId": "999913249",
            "orgName": "H. LUNDBECK AS",
            "ecContrib": 0
        },
        "937666409": {
            "orgId": "937666409",
            "orgName": "UCB Biopharma SPRL",
            "ecContrib": 0
        },
        "965288323": {
            "orgId": "965288323",
            "orgName": "EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION",
            "ecContrib": 78000
        },
        "999941379": {
            "orgId": "999941379",
            "orgName": "ASTRAZENECA AB",
            "ecContrib": 0
        },
        "997585928": {
            "orgId": "997585928",
            "orgName": "Eli Lilly and Company Ltd",
            "ecContrib": 0
        },
        "998928893": {
            "orgId": "998928893",
            "orgName": "FORUM EUROPEEN DES PATIENTS (FPE)",
            "ecContrib": 78000
        },
        "998873700": {
            "orgId": "998873700",
            "orgName": "Danish Health and Medicines Authority",
            "ecContrib": 0
        },
        "953198437": {
            "orgId": "953198437",
            "orgName": "ASTELLAS PHARMA EUROPE LTD",
            "ecContrib": 0
        },
        "952415259": {
            "orgId": "952415259",
            "orgName": "Lysogene",
            "ecContrib": 0
        },
        "997658387": {
            "orgId": "997658387",
            "orgName": "INSTITUT DE RECHERCHES INTERNATIONALES SERVIER",
            "ecContrib": 0
        },
        "997517058": {
            "orgId": "997517058",
            "orgName": "Amgen NV",
            "ecContrib": 0
        },
        "999965241": {
            "orgId": "999965241",
            "orgName": "MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN",
            "ecContrib": 0
        },
        "998096827": {
            "orgId": "998096827",
            "orgName": "MASSACHUSETTS INSTITUTE OF TECHNOLOGY",
            "ecContrib": 0
        },
        "997654895": {
            "orgId": "997654895",
            "orgName": "European Medicines Agency",
            "ecContrib": 0
        },
        "997656350": {
            "orgId": "997656350",
            "orgName": "STICHTING LYGATURE",
            "ecContrib": 522000
        },
        "999601782": {
            "orgId": "999601782",
            "orgName": "F. HOFFMANN-LA ROCHE AG",
            "ecContrib": 0
        },
        "952706065": {
            "orgId": "952706065",
            "orgName": "European Federation of Pharmaceutical Industries and Associations",
            "ecContrib": 0
        },
        "984454262": {
            "orgId": "984454262",
            "orgName": "NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE",
            "ecContrib": 232500
        },
        "998198095": {
            "orgId": "998198095",
            "orgName": "SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT",
            "ecContrib": 0
        },
        "957780426": {
            "orgId": "957780426",
            "orgName": "IPSEN INNOVATION S.A.S.",
            "ecContrib": 0
        },
        "999940021": {
            "orgId": "999940021",
            "orgName": "NOVO NORDISK A/S",
            "ecContrib": 0
        },
        "958496383": {
            "orgId": "958496383",
            "orgName": "Haute Autorité de Santé",
            "ecContrib": 28000
        },
        "927359189": {
            "orgId": "927359189",
            "orgName": "AbbVie Ltd",
            "ecContrib": 0
        },
        "999984350": {
            "orgId": "999984350",
            "orgName": "THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD",
            "ecContrib": 135500
        },
        "954738118": {
            "orgId": "954738118",
            "orgName": "Zorginstituut Nederland",
            "ecContrib": 28000
        },
        "912937132": {
            "orgId": "912937132",
            "orgName": "Shire International GmbH",
            "ecContrib": 0
        }
    },
    "calculatedTotalContribution": 1102000
}